ClinicalTrials.gov
ClinicalTrials.gov Menu

Analysis of the Results of Treatment for Cervical Carcinoma in Limburg (CervixLimburg)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT01059695
Recruitment Status : Completed
First Posted : February 1, 2010
Last Update Posted : January 14, 2015
Sponsor:
Collaborators:
Maastricht University Medical Center
Atrium Medical Center
Information provided by (Responsible Party):
Maastricht Radiation Oncology

Brief Summary:
Analysis of all women treated for cervical cancer between 2000 and 2008 in Limburg, a province in the south of the Netherlands. Patient characteristics, diagnosis, treatment modalities, complications and survival will be analyzed by record review. Quality of life of the living study population will be assessed using the EORTC QLQ-C30 and QOQ-CX24 questionnaire. Patients will be identified via registration data from the Integraal Kankercentrum Limburg.

Condition or disease
Cervical Cancer

Study Type : Observational
Actual Enrollment : 220 participants
Observational Model: Cohort
Time Perspective: Retrospective
Official Title: Retrospective Analysis of Treatment and Quality of Life of Women Treated for Cervical Carcinoma FIGO Stage IB-1 to IVb From 2000-2008 in Limburg, a Province in the South of the Netherlands.
Study Start Date : February 2010
Actual Primary Completion Date : February 2011
Actual Study Completion Date : July 2011

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Cervical Cancer
U.S. FDA Resources




Primary Outcome Measures :
  1. Quality of life
    Quality of life of the living study population will be assessed using the EORTC QLQ-C30 and QOQ-CX24 questionnaire



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   Child, Adult, Senior
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population
All women diagnosed with cervical cancer FIGO stage IB-1 to IV between 2000 and 2008 in Limburg, a province in the south of the Netherlands.
Criteria

Inclusion Criteria:

  • cervical cancer FIGO stage IB-1 to IVB
  • Treated in Limburg between 2000 and 2008

Exclusion Criteria:


Responsible Party: Maastricht Radiation Oncology
ClinicalTrials.gov Identifier: NCT01059695     History of Changes
Other Study ID Numbers: 09-24-09/12
First Posted: February 1, 2010    Key Record Dates
Last Update Posted: January 14, 2015
Last Verified: January 2015

Keywords provided by Maastricht Radiation Oncology:
cervical cancer
retrospective
quality of life
treatment

Additional relevant MeSH terms:
Uterine Cervical Neoplasms
Uterine Neoplasms
Genital Neoplasms, Female
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Uterine Cervical Diseases
Uterine Diseases
Genital Diseases, Female